金河生物(002688) - 2021 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 961,006,050.74, representing a 13.27% increase compared to CNY 848,429,942.59 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was CNY 117,482,792.85, an increase of 23.66% from CNY 95,005,448.80 in the previous year[20]. - The basic earnings per share increased by 20.00% to CNY 0.18 from CNY 0.15 in the same period last year[20]. - The total assets at the end of the reporting period were CNY 3,559,737,305.58, up 5.42% from CNY 3,376,867,194.00 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased by 3.16% to CNY 1,665,968,069.14 from CNY 1,614,883,310.48 at the end of the previous year[20]. - The net cash flow from operating activities was CNY 109,272,456.61, a decrease of 2.50% compared to CNY 112,070,629.44 in the same period last year[20]. - The company reported a significant increase in financial expenses by 86.80% to ¥34,189,635.99, primarily due to foreign exchange losses[52]. - The company reported a net profit margin improvement, with retained earnings increasing to CNY 506,946,082.80 from CNY 452,992,255.45, a growth of approximately 11.9%[164]. Revenue Breakdown - The revenue from veterinary chemical drugs was 490.7 million CNY, up 11.20% year-on-year, accounting for 51.06% of total revenue[35]. - The revenue from veterinary biological products reached 160.7 million CNY, a significant increase of 80.85% year-on-year, making up 16.73% of total revenue[35]. - The revenue from environmental protection business was 34.4 million CNY, reflecting a year-on-year increase of 13.21%[35]. - Domestic sales accounted for 65.12% of total revenue, increasing by 27.35% year-on-year, while international sales decreased by 6.12% to 34.88% of total revenue[55]. - The revenue from veterinary biological products surged by 80.85% to ¥160,739,150.45, significantly contributing to overall growth[55]. Operational Challenges - The company faced challenges from the African swine fever and COVID-19, which affected the livestock industry and sales orders[36]. - The average price of corn starch, a key raw material, rose by about 47% compared to the same period last year, impacting production costs[38]. - The company faced various operational risks, which are detailed in the report[4]. - The company faced risks from rising raw material prices, particularly corn, which significantly impacts the cost of its main product, and is implementing measures to mitigate these costs[85]. - The ongoing African swine fever epidemic continues to affect the demand for animal health products, prompting the company to enhance its product competitiveness and marketing efforts[86]. Investment and Development - The company completed a non-public stock issuance project, and the new development strategy is now in the execution phase[49]. - The company established a new subsidiary, Inner Mongolia Jinhai Pharmaceutical Technology Co., Ltd., to implement the doxycycline project[50]. - The company set up a pet division to explore the pet medication market and is in the process of applying for new veterinary drug certificates[50]. - The company has made substantial investments in new product development, particularly in vaccines, which have shown a high gross profit margin and strong sales growth[60]. - The total investment amount for the reporting period was ¥130,721,007.94, representing a year-on-year increase of 187.21% compared to ¥45,513,314.34 in the same period last year[70]. Environmental Compliance - The company reported a total emission of 8.166 tons of particulate matter, with a concentration of 14.28 mg/m³, which is below the standard limit of 30 mg/m³[94]. - The sulfur dioxide (SO2) emissions amounted to 52.611 tons, with a concentration of 85.59 mg/m³, also compliant with the standard limit of 200 mg/m³[94]. - Nitrogen oxides (NOX) emissions were recorded at 90.973 tons, with a concentration of 153.90 mg/m³, adhering to the standard limit of 200 mg/m³[94]. - The company has implemented a "three-level alkaline spray absorption + one-level adsorption" process for treating waste gas, ensuring compliance with national standards[98]. - The company has established itself as a leader in industrial wastewater treatment and solid waste management, providing comprehensive solutions[98]. Shareholder and Equity Information - The company issued 145,132,743 shares of common stock (A-shares) to 10 specific investors, with the stock listed on August 12, 2021[136]. - The total approved guarantee amount for subsidiaries at the end of the reporting period was CNY 74,800.2 million, with an actual guarantee balance of CNY 40,440.09 million, representing 24.27% of the company's net assets[132]. - The company reported a total of CNY 12,920.20 million in guarantees during the reporting period[132]. - The total number of ordinary shareholders at the end of the reporting period was 35,819[146]. - The company has implemented a 75% lock-up on shares held by directors and senior management[143]. Research and Development - Research and development expenses rose by 5.69% to ¥38,107,298.08 from ¥36,054,676.90, indicating continued investment in innovation[52]. - The company has established a research and development center recognized by local authorities, enhancing its innovation capabilities[104]. - The company is accelerating the registration of vaccine products, including live vaccines for sheep and goats, and inactivated vaccines for pigs[49]. Legal and Compliance - The company has not faced any significant legal disputes or non-compliance issues during the reporting period, maintaining a clean legal standing[105]. - There were no administrative penalties due to environmental issues during the reporting period, indicating strong compliance with environmental laws[104]. - The company was fined 20,000 yuan for using absolute terms in advertising and has since deleted the related content[117].